DETAILED ACTION
Applicant’s response filed 07/29/2026 has been fully considered. Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Claims 1-7, 9-10, 13-14, and 16-17 are pending and under consideration in this action.
Claim 15 was canceled in the amendment filed 07/29/2026. Claims 8 and 11-12 were previously canceled.
Priority
The instant application is a 371 of PCT/EP2020/058843, filed 3/27/2020, which claims priority to EPO Application Number 19165769.1, filed 3/28/2019, as reflected in the filing receipt mailed on 2/10/2022. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119 (a)-(d). Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. The claims to the benefit of priority are acknowledged and the effective filing date of claims 1-7, 9-10, and 13-14, and 16-17 is 3/28/2019.
Claim Rejections - 35 USC § 112(b)
Newly Recited Rejections
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 17 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
This rejection is newly recited and necessitated by claim amendment.
Claim 17 recites “a non-transitory computer readable medium, the computer readable medium having computer readable code embodied therein, the computer readable code being configured such that, on execution by a suitable computer or processor, the computer or processor is caused to perform the method of claim 1”. The metes and bounds of the claim are rendered indefinite due to the lack of clarity. Claim 1, to which claim 17 depends, recites the limitation “administering, to the subject, at least one of the prescribed dose of radiation or the immunotherapy treatment in accordance with the modified treatment protocol”. Claim 17 requires a processor to perform all the steps of claim 1. It is unclear what parameters or steps would be required for the same processor performing to the analysis of the patient, treatment, and imaging data to also perform the administration of the modified treatment (either radiation or immunotherapy). Clarification through clearer claim language is respectfully requested.
Claim Rejections - 35 USC § 101
The rejection of claims 1-7, 9-10, and 13-17 under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea without significantly more is withdrawn in view of Applicant’s amendments to the claims filed 07/29/2026 (Applicant’s Remarks, Pg. 6-7).
With regards to claim 1, as amended, the limitation of “administering, to the subject, at least one of the prescribed dose of radiation or the immunotherapy treatment in accordance with the modified treatment protocol” integrates the recited judicial exceptions into a practical application under Step 2A, Prong Two by providing a particular treatment to a subject with a risk of hematologic toxicity above a threshold.
With regards to claim 16, as amended, the limitation “process the treatment data and the imaging data to determine a received dose of radiation to be delivered to the one or more radiation-sensitive tissues in the subject during the particular radiotherapy treatment session, wherein determining the received dose comprises co-registering each of the plurality of images into a reference patient geometry and summing the co-registered fraction doses up to and including a current fraction” recites an additional element. While the process of co-registering images to a reference geometry is well-understood, routine, and conventional, the process of co-registering using the images up to and including a current fraction during a particular radiotherapy treatment to determine the dose is not well-understood, routine, and conventional. Accordingly, this limitation reflects a specific improvement in the determination of the received dose of radiation during a particular treatment session, and therefore transforms the judicial exception into a patent-eligible application under Step 2B (see Applicant’s Remarks, Pg. 6-7).
Conclusion
Claims 1-7, 9-10, 13-14, and 16 are allowed.
Claim 17 is rejected.
Claims 1-7, 9-10, 13-14, and 16-17 appear to be free from the prior art for the same reasons as disclosed in the Conclusion section of the Office action mailed 04/01/2026.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Inquiries
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DIANA P SANFORD whose telephone number is (571)272-6504. The examiner can normally be reached Mon-Fri 8am-4:30pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Karlheinz Skowronek can be reached at (571)272-9047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/D.P.S./Examiner, Art Unit 1687
/Lori A. Clow/Primary Examiner, Art Unit 1687